Similar effects are expected from Tideglusib, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, not yet FDA-approved, mainly investigated for AD and progressive supranuclear palsy treatments (Lovestone et al., 2015; Stamelou et al., 2016). Here, GSK3B is linked to Classical progressive supranuclear palsy.